Regentis Receives Japanese Patent for GelrinC Manufacturing Technology
Regentis Biomaterials Ltd. announced that the Japan Patent Office has issued a Notice of Allowance for its patent application covering the proprietary organic solvent-free manufacturing process and ready-to-use liquid formulation used in GelrinC. This allowance significantly strengthens the company's global intellectual property portfolio for its regenerative treatment for articular cartilage injuries. The technology offers important manufacturing advantages, including a 5x increase in yield, enhanced environmental profile, and simplified production, supporting future commercialization opportunities in major international markets like Japan, where the cartilage repair market is projected to reach $289 million by 2030.
Key Highlights
- Japanese Patent Office issued Notice of Allowance for GelrinC manufacturing process.
- Patent strengthens global intellectual property portfolio for GelrinC.
- Proprietary manufacturing technology improves process efficiency by 5x in yield.
- Japan's cartilage repair market is estimated to reach $289 million by 2030.
- Approximately 25 million people in Japan over 40 have radiographic knee osteoarthritis.
- GelrinC is a cell-free hydrogel for focal articular knee cartilage injuries.
- GelrinC has CE Mark approval and is over 50% enrolled in a pivotal U.S. FDA study.
Price Impact
More from RGNT